Research programme: CNS disorders therapies - Cephalon/Transition Therapeutics

Drug Profile

Research programme: CNS disorders therapies - Cephalon/Transition Therapeutics

Latest Information Update: 27 Oct 2011

Price : $50

At a glance

  • Originator Cephalon; Transition Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued CNS disorders

Most Recent Events

  • 14 Apr 2010 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
  • 07 Nov 2005 Protana has been acquired and merged into Transition Therapeutics
  • 18 Aug 2004 MDS Proteomics is now called Protana
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top